Anton Törnqvist Andrén

Anton Törnqvist Andrén has worked in a range of roles since 2013. Anton started as a Research Engineer at Karolinska institutet, followed by a Research Associate role at the National Pandemic Center, where they were responsible for inactivation and registration of thousands of COVID-19 tests and training of new personnel. Anton then worked as a Research Technician, partly responsible for transferring the production of primary bone marrow derived hMSC from pre-GMP to GMP and making it an advanced therapy medicinal product (ATMP). In 2021, they moved to Procella Therapeutics AB as a Bioprocessing Research Associate, and in 2022, they joined XNK Therapeutics as a Scientist.

Anton Törnqvist Andrén attended Stockholm University from 2015 to 2016, where they earned a Master's degree in Molecular life sciences.